Presentation by Dr. Caty Ebel Bitoun, Global Medical Digital Transformation Head, Sanofi, for the mHealth Israel community, April 12, 2021. Begins with an overview and description of Sanofi worldwide. Explanatio of Sanofi's three Global Business Units (GBU) focused on prioritized portfolio. 1st GBU is Specialty Care: Immunology, Rare Diseases / Rare Blood Disorders, Neurology / Multiple Sclerosis, Oncology; 2nd GBU is General Medicines: Diabetes, Cardiovascular, Established Products; 3rd GBU is Vaccines: Influenza vaccines, Polio Pertussis & Hib, Boosters, Meningitis, others. There is also a standalone GBU for Consumer Healthcare: Allergy, Cough & Cold, Pain, Digestive Health, Mental Wellness. Digital is changing the healthcare landscape. Empowering patients / consumers and organising self monitoring. Digital improves patient information and product usage with sustainibility value proposition. Digital Therapeutics are opening a new way to manage pain. Sanofi Ideal partner profile has Mature technology including mature business model. Scalable across more than 2 geographies. Compliance with cybersecurity and data protection. Sustainibility value proposition. Easy to purchase (onsite & e-commerce). Impact on consumers includes Consumer focus. Proven improvement in health or lifestyle outcome. Data driven claims supported by scientific evidence. Augmented consumer experience. Sanofi has a partner centric philosophy.

1. How Digital
Transformation
creates new
opportunities
for
self-medication
Dr Caty Ebel Bitoun
CHC Global Medical Digital
Transformation Head
April 12th 2021

2. Who we are
2
AROUND THE WORLD OUR TEAMS
100,000+
employees
46.2%
women
53.8%
men
~145
nationalities
We are present in
~100 countries
Healthcare solutions available in more than
170 countries
TRANSTECH HEALTH APRIL 12TH 2021

3. Sanofi Global Business Unit (GBU) organization
3
3 CORE GBUs FOCUSED ON PRIORITIZED PORTFOLIO
Specialty Care
— Immunology
— Rare Diseases /
Rare Blood Disorders
— Neurology /
Multiple Sclerosis
— Oncology
General Medicines
— Diabetes
— Cardiovascular
— Established Products
Vaccines
— Influenza vaccines
— Polio Pertussis & Hib,
Boosters
— Meningitis, others
STANDALONE GBU
Consumer Healthcare
— Allergy, Cough & Cold
— Pain
— Digestive Health
— Mental Wellness
TRANSTECH HEALTH APRIL 12TH 2021

4. Sanofi CHC is leading in 4 global OTC categories
TRANSTECH HEALTH APRIL 12TH 2021

5. Digital is changing the healthcare landscape
Empowering patients / consumers and organising self monitoring
5
TRANSTECH HEALTH APRIL 12TH 2021
https://www.efpia.eu/about-medicines/development-of-
medicines/digital-health/

6. How digital improve patient information and product usage
with sustainibility value proposition
TRANSTECH HEALTH APRIL 12TH 2021
https://www.sanofi-diabete.fr/notre-
engagement/actualites/diab-voyage

7. 7
A concrete example from Sanofi France
Digital Therapeutic : Opening a new way to manage pain
TRANSTECH HEALTH APRIL 12TH 2021

8. 8
A concrete example from Sanofi Venture & Alive Israel HealthTech fund
Beyond the pill : How digital helps to self manage medication
TRANSTECH HEALTH APRIL 12TH 2021

9. Building the ecosystem

10. Our Ideal partner profile
Consumer focus
Augmented consumer
experience
Mature technology
including mature
business model
Scalable more than 2
geographies
Proven improvement in
health or lifestyle
outcome
Impact on our consumers
Profile of the technology
Sustainibility value
proposition
Easy to purchase
(onsite & e-commerce)
Data driven claims
supported by scientific
evidence
TRANSTECH HEALTH APRIL 12TH 2021
Compliance cybersecurity
and data protection

11. Sanofi has a partner centric philosophy
TRANSTECH HEALTH APRIL 12TH 2021

12. THANK YOU
Contact:
Dr Caty Ebel Bitoun
Caty.ebel-bitoun@sanofi.com